NCT05296317View on ClinicalTrials.gov

Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

September 2, 2025

Study Completion Date

October 2, 2025

Conditions
Localized Breast Cancer
Interventions
DRUG

Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)

"\- Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14"

DRUG

Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)

"\- Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14"

Trial Locations (1)

21000

RECRUITING

Centre Georges François Leclerc (CGFL), Dijon

All Listed Sponsors
lead

Centre Georges Francois Leclerc

OTHER